Replies to post #79139 on PharmaCyte Biotech Inc (PMCB)

[1234jklm]

Von hoff hasn't agreed to consult

The Lohr trial for ascites failed in its most recent trial.

So it's not impossible that the pancreatic cancer trial might also fail to reproduce lohrs 20 year old tumor reductions results.

We can't retrieve encapsulated cells which is an FDA requirement according to jdrf.

Mellingen cells don't work at the moment and aren't rebuilt yet, we don't even know if if they can be.

We don't have a CRO.

It's almost a year since the pre ind.

Other pancreatic and encapsulated beta cell diabetes treatments by MIT seem ahead of us with 150million in funding backing them.

Genetic cancer treatments are becoming better and cheaper every day.

Let's not get ahead of ourselves here.

I love the glee as much as anyone but let's deal with reality.

It's very likely that we've missed the boat on cancer and diabetes.